Financhill
Sell
46

TECX Quote, Financials, Valuation and Earnings

Last price:
$19.89
Seasonality move :
-11.53%
Day range:
$19.84 - $21.49
52-week range:
$13.70 - $61.07
Dividend yield:
0%
P/E ratio:
--
P/S ratio:
--
P/B ratio:
1.31x
Volume:
251.4K
Avg. volume:
538.3K
1-year change:
-61.14%
Market cap:
$372.8M
Revenue:
--
EPS (TTM):
-$3.85

Analysts' Opinion

  • Consensus Rating
    Tectonic Therapeutic, Inc. has received a consensus rating of Buy. The company's average rating is a Buy based on 6 Buy ratings, 0 Hold ratings, and 0 Sell ratings.
  • Price Target Upside
    According to analysts' consensus price target of $78.71, Tectonic Therapeutic, Inc. has an estimated upside of 295.15% from its current price of $19.92.
  • Price Target Downside
    According to analysts, the lowest downside price target is $64.00 representing 100% downside risk from its current price of $19.92.

Fair Value

  • According to the consensus of 6 analysts, Tectonic Therapeutic, Inc. has 295.15% upside to fair value with a price target of $78.71 per share.

TECX vs. S&P 500

  • Over the past 5 trading days, Tectonic Therapeutic, Inc. has underperformed the S&P 500 by -7.38% suggesting its relative strength compared to the major market average is weak at this time.

Share Buyback

  • Tectonic Therapeutic, Inc. does have a share repurchase program in place at this time. The scale of a buyback program can materially affect share price and usually results in a higher earnings per share, all else being equal, when the share count drops.

Revenue Growth

  • Tectonic Therapeutic, Inc. has grown year-over-year revenues for 0 quarters straight. In the most recent quarter Tectonic Therapeutic, Inc. reported revenues of --.

Earnings Growth

  • Tectonic Therapeutic, Inc. has grown year-over-year earnings for 6 quarters straight. In the most recent quarter Tectonic Therapeutic, Inc. reported earnings per share of -$1.02.
Enterprise value:
104.4M
EV / Invested capital:
--
Price / LTM sales:
--
EV / EBIT:
--
EV / Revenue:
--
PEG ratio (5yr expected):
--
EV / Free cash flow:
-1.62x
Price / Operating cash flow:
--
Enterprise value / EBITDA:
--
Gross Profit (TTM):
-$1.2M
Return On Assets:
-27.84%
Net Income Margin (TTM):
--
Return On Equity:
-29.43%
Return On Invested Capital:
-29.15%
Operating Margin:
--
Trailing 12 Months Fiscal Quarters
Period Ending 2023-09-30 2024-09-30 2025-09-30 2024-09-30 2025-09-30
Income Statement
Revenue -- -- -- -- --
Gross Profit -$4.6M -$1.4M -$1.2M -$424K --
Operating Income -$71.2M -$53.4M -$76.5M -$19.6M -$21.9M
EBITDA -$66.6M -$52M -- -$19.2M --
Diluted EPS -$207.22 -$22.10 -$3.85 -$1.20 -$1.02
Period Ending 2021-09-30 2022-09-30 2023-09-30 2024-09-30 2025-09-30
Balance Sheet
Current Assets $211.7M $126.2M $109.2M $162.6M --
Total Assets $216.5M $129.5M $110.5M $168.7M $277M
Current Liabilities $22.8M $16.2M $7.6M $17.3M --
Total Liabilities $22.9M $31.4M $7.7M $18.4M --
Total Equity $193.6M $98.1M $102.9M $150.4M $267.5M
Total Debt -- $15.2M $105K $1.5M --
Trailing 12 Months Fiscal Quarters
Period Ending 2023-06-30 2024-06-30 2025-06-30 2024-06-30 2025-06-30
Cash Flow Statement
Cash Flow Operations -$60.6M -$44.5M -$64.2M -$15.1M -$14.7M
Cash From Investing -$308K -$61K -$128K -- $55K
Cash From Financing -$150K $212.4M $166.6M $179M -$4.2M
Free Cash Flow -$60.9M -$44.6M -$64.4M -$15.1M -$14.7M
TECX
Sector
Market Cap
$372.8M
$28.5M
Price % of 52-Week High
32.62%
51.44%
Dividend Yield
0%
0%
Shareholder Yield
-59.42%
-1.33%
1-Year Price Total Return
-61.14%
-20.32%
Beta (5-Year)
1.566
0.520
Dividend yield:
0%
Annualized payout:
$0.00
Payout ratio:
--
Growth streak:
0 years

Technicals

8-day SMA
Sell
Level $20.59
200-day SMA
Sell
Level $20.25
Bollinger Bands (100)
Buy
Level 16.15 - 22.51
Chaikin Money Flow
Sell
Level -11.8M
20-day SMA
Buy
Level $19.46
Relative Strength Index (RSI14)
Buy
Level 53.38
ADX Line
Buy
Level 35.43
Williams %R
Neutral
Level -48.037
50-day SMA
Buy
Level $17.92
MACD (12, 26)
Buy
Level 0.68
25-day Aroon Oscillator
Buy
Level 60
On Balance Volume
Neutral
Level 4.8M

Financial Scores

Buy
Altman Z-Score (Annual)
Level (32.3799)
Sell
CA Score (Annual)
Level (-4.1412)
--
Beneish M-Score (Annual)
Level (--)
Sell
Momentum Score
Level (2)
Sell
Ohlson Score
Level (7.4244)
--
Piotroski F Score (Annual)
Level (--)
Sell
Quality Ratio Score
Level (1)
Sell
Fundamental Score
Level (0)

Revenue Forecast

Earnings per Share Forecast

Company Profile

Tectonic Therapeutic, Inc. is a clinical-stage biotechnology company, which engages in the discovery and development of therapeutic proteins and antibodies that modulate the activity of G protein-coupled receptors (GPCR). It develops a proprietary technology platform called GEODe to enable the discovery and development of GPCR-targeted biologic medicines. The company was founded by Timothy A. Springer and Andrew Kruse in November 2015 and is headquartered in Watertown, MA.

Stock Forecast FAQ

In the current month, TECX has received 6 Buy ratings 0 Hold ratings, and 0 Sell ratings. The TECX average analyst price target in the past 3 months is $78.71.

  • Where Will Tectonic Therapeutic, Inc. Stock Be In 1 Year?

    According to analysts, the consensus estimate is that Tectonic Therapeutic, Inc. share price will rise to $78.71 per share over the next 12 months.

  • What Do Analysts Say About Tectonic Therapeutic, Inc.?

    Analysts are divided on their view about Tectonic Therapeutic, Inc. share price and where it will be in the next 12 months. The majority of analysts rate the stock a Buy. However, a smaller subset of analysts suggest that Tectonic Therapeutic, Inc. is a Sell and believe this share price will drop from its current level to $64.00.

  • What Is Tectonic Therapeutic, Inc.'s Price Target?

    The price target for Tectonic Therapeutic, Inc. over the next 1-year time period is forecast to be $78.71 according to 6 Wall Street analysts, 6 of them rate the stock a Buy, 0 rate the stock a Sell, and 0 analysts rate the stock a Hold.

  • Is TECX A Buy, Sell Or Hold?

    According to Wall Street analysts, the consensus rating for Tectonic Therapeutic, Inc. is a Buy. 6 of 6 analysts rate the stock a Buy at this time.

  • How Can I Buy Shares Of TECX?

    You can purchase shares of Tectonic Therapeutic, Inc. via an online brokerage firm such as TD Ameritrade.com, thinkorswim.com, e-trade.com, or Schwab.com. Many other digital online brokerages exist such as RobinHood and Webull where you can purchase Tectonic Therapeutic, Inc. shares.

  • What Is The Tectonic Therapeutic, Inc. Share Price Today?

    Tectonic Therapeutic, Inc. was last trading at $19.89 per share. This represents the most recent stock quote for Tectonic Therapeutic, Inc.. Yesterday, Tectonic Therapeutic, Inc. closed at $19.92 per share.

  • How To Buy Tectonic Therapeutic, Inc. Stock Online?

    In order to purchase Tectonic Therapeutic, Inc. stock online, open a brokerage account, deposit funds into the account, and select an order type to purchase shares whether it be market or limit.

SEE THE 1% OF STOCKS YOU NEED TO OWN FOR MASSIVE RETURNS

GET BETTER TRADE IDEAS

Popular

Why Did SoFi Stock Drop?
Why Did SoFi Stock Drop?

Fintech platform SoFi (NASDAQ:SOFI) has stumbled in recent days, selling…

Will Robinhood Win AI Investing?
Will Robinhood Win AI Investing?

Recently, online brokerage Robinhood (NASDAQ:HOOD) has been focused on introducing…

Is Amazon an AI Stock?
Is Amazon an AI Stock?

With the market starting to look skittish on pure-play AI…

Stock Ideas

Buy
52
Is NVDA Stock a Buy?

Market Cap: $4.4T
P/E Ratio: 62x

Buy
56
Is AAPL Stock a Buy?

Market Cap: $4.1T
P/E Ratio: 37x

Buy
81
Is GOOG Stock a Buy?

Market Cap: $3.9T
P/E Ratio: 40x

Alerts

Buy
56
SMX alert for Dec 6

SMX (Security Matters) Plc [SMX] is up 134.09% over the past day.

Buy
62
PRAX alert for Dec 6

Praxis Precision Medicines, Inc. [PRAX] is up 30.47% over the past day.

Sell
13
PSN alert for Dec 6

Parsons Corp. [PSN] is down 21.1% over the past day.

THE #1 STOCK ANALYSIS TOOL
TO MAKE SMARTER BUY AND SELL DECISIONS

Show me the best stock